Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Pragmatiston Apr 27, 2020 1:34am
693 Views
Post# 30956227

Will Trial Results Be Sufficiently Conclusive?

Will Trial Results Be Sufficiently Conclusive?I am concerned that Antibe’s trial results will be inconclusive.  Results from previous trials have not demonstrated with any degree of certainty that ATE 346 will achieve comparable pain relief with higher doses of Naproxen.  There are some strong indicators, but do these provide sufficient proof?  Also, the earlier phase 2 trial showed significant reductions in adverse gastrointestinal effects.  But were these due mainly to the H2S additive, or more   due to the much lower Naproxen content in the drug?  One would expect that the adverse effects of Naproxen would increase in a non-linear relation with dosage.  Why did the trial compare ATE 346 250 mg with the prescription dosage of Naproxen, and not the much lower over-the-counter maximum dosage ( max 440 mg per day for pers over 65, the age group most likely to suffer from osteoarthritis).  Would 440 mg per day Naproxen produce similar results as ATE 346?
 
I am concerned that the results will be inconclusive because of the subjective nature of the WOMAC scoring system.  Also, the variance in the  amounts of ATB 346 Naproxen being investigated in the efficacy study  are quite low. Will 150 mg of Naproxen produce a significant change in WOMAC scoring than 200mg?  Will pain relief with 200mg be significantly different with that of 250mg?  How much will the “placebo effect”  come into play?  Will these small variances in dosage, combined with the varying degrees of osteoarthritis pain  suffered by trial participants produce inconsistent results?  How would inconsistent results affect share price?  (check out ACASTI Pharmaceuticals!)
 
Worst case results from the trial:  No statistical differences in the WOMAC scores and the various dosages/placebo.  Slightly better case, some positive but inconsistent results.  Best case,  results as hoped for, all shareholders get rich, and the world is in a much better place.
 
I suspect that there are a lot of anxious shareholders with their fingers on the sell button.  I wish you all the best and hope the soon to be released news is extremely positive

Bullboard Posts